Use of pharmacotherapy for alcohol use disorder in Manitoba, Canada: A whole-population cohort study.
PLoS One
; 16(9): e0257025, 2021.
Article
in En
| MEDLINE
| ID: mdl-34478448
ABSTRACT
OBJECTIVE:
Update the evidence on use of pharmacotherapy for alcohol use disorder in a Canadian population.METHODS:
Using whole-population administrative data from Manitoba, Canada, we identified all residents age 12+ who were first diagnosed with alcohol use disorder between April 1, 1996 and March 31, 2015, and compared characteristics of those who filled a prescription for naltrexone, acamprosate or disulfiram at least once during that period to those who did not fill a prescription for an alcohol use disorder medication.RESULTS:
Only 1.3% of individuals with alcohol use disorder received pharmacotherapy (62.3% of prescriptions were for naltrexone, 39.4% for acamprosate, 7.5% for disulfiram). Most prescriptions came from family physicians in urban alcohol use disorder (53.6%) and psychiatrists (22.3%). Individuals were more likely to fill a prescription for alcohol use disorder medication if they lived in an urban vs rural environment (OR 2.25; 95% CI 1.83-2.77) or had a mood/anxiety disorder diagnosis vs no diagnosis (OR 2.40, 95% CI 1.98-2.90) in the five years before being diagnosed with alcohol use disorder.CONCLUSION:
Despite established evidence for the effectiveness of pharmacotherapy for alcohol use disorder, these medications continue to be profoundly underutilized in Canada.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Alcohol Deterrents
/
Alcoholism
/
Acetaldehyde Dehydrogenase Inhibitors
/
Narcotic Antagonists
Type of study:
Etiology_studies
/
Incidence_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Adolescent
/
Adult
/
Aged
/
Child
/
Female
/
Humans
/
Male
/
Middle aged
Country/Region as subject:
America do norte
Language:
En
Journal:
PLoS One
Journal subject:
CIENCIA
/
MEDICINA
Year:
2021
Document type:
Article
Affiliation country:
Canada